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Principle
The idea that open access is good, for science and
society, seems to have gained a lot of currency of
late. Whereas it was widely ridiculed just a few
years ago, we now see even those who appeared to
be staunch opponents of open access admit that
there is something in it for science and society
(though not necessarily for themselves). We have
seen senior managers of major publishing com-
panies and scholarly societies express sentiments
from “How could one be against?” to “It is in the
public interest”, to “We have no problem with
open access”. That is clearly a gain for the concept
of open access as a principle. Nonetheless, these
words of support for the principle were attenuated
by qualifications such as “no problem with open
access per se” and “It’s moving too fast”.1
Perhaps it cannot be expected that those I quote
would fully support open access. After all, they
face tremendous practical difficulties. How to
maintain their level of profit to satisfy their
shareholders or level of ‘surplus’ to maintain their
good deeds, for instance? And at the same time,
how to satisfy their customers as well? A classic
case of being caught between a rock and a hard
place. To re-engineer a business is fiendishly
difficult. To do it in order to increase profit levels is
hard enough; to do it knowing that profit levels
might well go down seems just too much to ask.
Business managers must remain rational.
Unfortunately, we live in a science communica-
tion culture that makes it perfectly rational for
publishers to limit the dissemination of research
results. It also makes it perfectly rational to
increase prices regularly and virtually never to
decrease them, in the knowledge that the market is
quite inelastic: lowering prices will not likely result
in higher unit sales. Competition on price, there-
fore, does not exist.
The combined effect of these rational responses
leads to further limitations to dissemination and
further increases in costs to the scientific commu-
nity, making clear that the status quo is not a
realistic option for science publishing. 
In the UK, a cross-party parliamentary body, the
House of Commons Select Committee on Science
and Technology, held an inquiry into science
publishing and came back with recommendations
that “… the Research Councils and other Govern-
ment funders mandate their funded researchers to
deposit a copy of all their articles in their institu-
tion’s repository […] as a condition of their
research grant” and that “… the Research Councils
each establish a fund to which their funded
researchers can apply should they wish to publish
their articles using the author-pays model.”2
The UK Government responded that it “… is not
aware that there are major problems in accessing
scientific information, or that there is a large un-
satisfied demand for this.” Given the widespread
discussion of these problems, this seems a curious
response, but the Government did not wish to tilt
the “level playing field.”3 And how will the
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Department of Trade and Industry (of which the
Office of Science and Technology is a department)
achieve this? By establishing a ‘Research Com-
munications Forum’ with traditional publishers
represented but, at the time of writing, without
including any representation of UK open access
publishers! Must be one of those mysterious ways
in which governments work, perhaps.
The Government response was greeted with
relief by the STM publishers. Doesn’t this contra-
dict their professed support for the principle of
open access, though? Or is this one of those mys-
terious ways in which the STM industry works,
perhaps? In the words of Robert Campbell, presi-
dent of Blackwell Publishing: “A triumph of
common sense over ideology; obviously, we are
glad that the Government supports a successful
industry.” 
Phew! Victory. 
Curiously, in the weeks after the Government
response, the inflow of articles to the open access
journals published by BioMed Central experienced
an acceleration that hasn’t abated yet. Complete
coincidence, of course, but who knows? Perhaps
the STM publishers might contemplate the words
of king Pyrrhus of Epirus after the battle of
Tarentum in which he lost half his men: “Another
such victory and I shall be ruined!”
One thing is clear: open access is here to stay. 
Practice
Whilst open access is becoming an accepted
principle, its implementation in practice is still best
described as a drop in the ocean. Why is something
that is so desirable and useful so slow in develop-
ing a critical mass? One reason may be that
researchers live in what I like to call an ‘ego-
system’. Few researchers can escape its effects.
They have to survive and thrive in the system, and
publishing in the highest journals in the pecking
order of their field is often an imperative. Promo-
tion and tenure assessment mechanisms rely to an
extraordinary degree on publications in long-
established journals. Researchers would benefit, as
would science as a whole, from the maximum dis-
semination of their papers that comes with open
access, but they understandably try to get their
papers published in those long-established con-
ventional journals due to the pressure of potential
promotion. The system thus disproportionately
favours incumbent journals over open access
journals, most of which are, of necessity, new. As a
result there is a high degree of inertia in the
publishing culture of science. 
As users of science literature, researchers are
often ignorant of the costs of publishing. The effect
of rising costs – limited access to the literature,
sometimes severely so, due to the unaffordability
of comprehensive access – is often blamed on the
libraries and institutions, not on the system of
publishing.
The dilemma that many a scientist faces is this:
publishing with open access is better for science
but not for me; publishing in a traditional journal
is better for me but not for science.
Of course, publishing in open access journals is
not the only way to achieve open access. The alter-
native is self archiving. The best of both worlds, on
the face of it. One can publish in an established
journal and immediately deposit a version in an
openly accessible institutional or subject-oriented
repository. That certainly relieves the symptoms of
the old restrictive model. As such it is extremely
useful and ought to be encouraged. But we at
BioMed Central, and a few other open access pub-
lishers, seek to remove the root cause of limited
access. We want to offer solutions that transform
the entire publishing system and make open access
the central achievement of the process. 
Scholarly societies face a dilemma, too. Their
fear is that self archiving may undermine the
income they have hitherto enjoyed from subscrip-
tions. There is some logic to that argument, of
course. Why would a library subscribe if the
content of a journal is available for free? Especially
now that open repositories are becoming both
more sophisticated and widespread, and teething
problems of searching across, and harvesting from,
many different repositories are disappearing. On
the other hand, societies feel the need to adhere to
their mission, which almost universally includes
the ‘spread of knowledge’. Should they try to keep
the surf back – King Canut-like – or should they
ride the open access wave? The solution we favour
is that societies look very seriously into the
economic possibilities of open access publishing
(and such possibilities do exist!), so that they do
not risk losing all.
The parties that are in a position simultaneously
to influence the promotion system as well as the
publishing models are the research funding
bodies. Few dilemmas for them, one would have
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thought. And indeed, it is becoming clear that the
leading role of some visionary funders, such as the
Wellcome Trust, is making a major difference with
regard to the progress of open access. A funding
body can give succour to a researcher who might
hesitate to publish in an open access journal in
three important ways: firstly, by footing the bill for
any reasonable article charges; secondly, by giving
reassurance that for future funding they will assess
the quality of the articles themselves rather than
just look at the reputation of the journal in which
they are published and, thirdly, by recognizing the
intrinsic merit of contributions to an open access
infrastructure by the publication in open access
journals, thus enhancing the general reputation of
scientists in the public eye.
Progress
Progress is still fairly slow, as is to be expected for
a process that is little less than a complete cultural
change with regard to the publishing behaviour 
of research scientists. Publishers would not be 
expected to change until they have to. Even so, a
number of publishers have started to experiment
seriously with open access. And the new titles
being added to BioMed Central’s list show no sign
of slowing down. Neither does the aggregate
article inflow to our open access titles. 
A number of persistent misunderstandings still
dog the development of open access. Many mis-
understandings and myths are kept alive and per-
petuated by the traditional publishers. For instance
there is the idea that open access publishing is not
economically viable, because the model of paying
upfront, for unlimited dissemination, rather than
paying afterwards, for access, hasn’t proven itself.
This betrays the extraordinary tunnel vision of the
science publishing industry, for they would only
have to look at other branches of their own
industry to see that there are major publishing
sectors working on precisely that model: it is the
model of advertising, of course. The pressures that
advertisers work under are not all that dissimilar to
the pressures on researchers. ‘Advertise or perish’
would for many be a completely recognizable
slogan. There are important differences between
advertising and publishing scientific research
results, of course, such as peer review. However,
the existence of peer review is not usually men-
tioned as a perceived economic impediment to an
upfront payment model. And there are striking
similarities. This analogy may be a bit uncomfort-
able, perhaps, but we’re looking at the financial
model, not the trustworthiness of the message. An
advertiser wants to disseminate information about
his product or service as widely as possible, aiming
to stimulate sales. Rather like what a researcher –
and his funder – wants to do with the results of his
research when he aims to achieve maximum
impact. It is ‘publish or perish’, is it not? For most
research results, ‘push’ achieves more than ‘pull’,
to use some terms borrowed from advertising. An
advertiser pays for the service. Why shouldn’t a
researcher and his backers? Isn’t publishing the
finishing touch of a research project that is other-
wise wholly financed upfront by its funders? Why
would the crucially important finishing touch 
be alone in being financed otherwise, especially if
that may compromise the impact of the project? Is
it not time science publishing recognized this reality?
Another misunderstanding is that traditional
publishers need to be protected by the scientific
community. Really? Why? The recent discussion
about the National Institutes of Health (NIH) plans
for depositing articles in PubMed Central seemed
to revolve completely around the potential damage
to traditional publishers. But isn’t it the task of
funders, and thus of their grantees, to get the maxi-
mum out of their investments and efforts? Should
their focus not be on the protection of the efficacy
of science? The concessions made, a proposed
delay in the open availability of the published
results of research that the NIH funded, are purely
serving to protect publishing interests and do
nothing to protect science and society as a whole
from the damage of restricted access. Given the need
for the NIH to be politically sensitive, the situation
may, more than anything, reflect the relative
lobbying strengths of the traditional publishing
industry over the new open access initiatives and
their advocates.
However, there is every reason to be optimistic
about open access. Misunderstandings and myths
are steadily being cleared, albeit perhaps more
slowly than originally hoped, and the realization
grows that the enterprise of science benefits from
sharing its research results freely and immediately
among its peers and with society at large.
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